Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer

Takiko Daikoku,1 Dingzhi Wang,2 Susanne Tranguch,3 Jason D. Morrow,4 Sandra Orsulic,5 Raymond N. DuBois2,3 and Sudhansu K. Dey1,2,4

Departments of Pediatrics,3 Medicine,2 Cell and Developmental Biology, Pharmacology, Division of Reproductive and Developmental Biology, Vanderbilt University Medical Center, Nashville, Tennessee and Massachusetts General Hospital Center for Cancer Research, Harvard Medical School, Charlestown, Massachusetts

Abstract
The precise genetic and molecular defects underlying epithelial ovarian cancer (EOC) remain largely unknown, and treatment options for patients with advanced disease are limited. Cyclooxygenases (COX-1 and COX-2) catalyze the conversion of arachidonic acid to prostaglandins. Whereas overwhelming evidence suggests a role for COX-2 in a variety of cancers, the contribution of COX-1 remains much less explored. The expression status of COX isoforms in ovarian cancers also remains confusing. We have previously shown that human epithelial ovarian tumors have increased levels of COX-1 but not COX-2. To more carefully examine the role of COXs in ovarian cancer, we used a mouse model of EOC in which genetic and oncogenic modifications were experimentally engineered into ovarian surface epithelial cells (OSE) thought to be the cells of origin for human EOC. These OSE cells produce tumors when allografted into host mice. Using multiple approaches, we observed that OSE cells and the tumors comprised of these cells express high levels of COX-1 but not COX-2. Prostacyclin (PGI2) is the major prostaglandin generated downstream of COX-1 in these cells, and SC-560, a COX-1-selective inhibitor, dramatically inhibits PGI2 production. More importantly, SC-560 reduced the growth of tumors when OSE cells were allografted in nude female mice. In contrast, the COX-2-selective inhibitor celecoxib had little effect on tumor growth. The growth inhibitory effects of SC-560 result from reduced cell proliferation and/or accelerated apoptosis. Our results imply COX-1 as a target for the prevention and/or treatment of EOC. (Cancer Res 2005; 65(9): 3735-44)

Introduction
The cyclooxygenases, COX-1 and COX-2, catalyze arachidonic acid to prostaglandin H2 (PGH2), which is then converted to various prostaglandins by specific synthases (1). Whereas COX-1 and COX-2 isoforms are encoded by separate genes, they have very similar structural and kinetic properties and show distinct cell-specific expression and regulation (1). COX-1 is considered a constitutive enzyme, whereas COX-2 is highly inducible by diverse stimuli including cytokines, growth factors, mitogens, and tumor promoters and also regulates inflammation, differentiation, mitogenesis, and angiogenesis (1). Nonsteroidal anti-inflammatory steroids (NSAID) primarily interfere with prostaglandin biosynthesis by inhibiting COX enzymes. Research primarily focusing on colorectal cancer has provided mounting evidence that NSAIDs are effective in cancer prevention and possibly for adjuvant therapy in the treatment of established tumors (2). These drugs impede colorectal cancer growth primarily by inhibiting COX-2, although other non-COX-2 targets cannot be ruled out. Furthermore, COX-2 is up-regulated in a range of extracolonic cancers, and selective COX-2 inhibitors have potent antineoplastic effects in vivo in preclinical models of various solid malignancies (2). These findings led to several clinical trials examining the efficacy of COX-2-selective inhibitors in primary and/or secondary prevention of cancer or as part of a combination therapy regimen for established tumors (2). Unfortunately, recent clinical results indicate that prolonged use of highly selective COX-2 inhibitors leads to increased myocardial infarctions and strokes.

Epidemiologic studies to examine whether NSAIDs prevent or delay the development of ovarian cancers remain inconclusive. Although several population- and hospital-based case-control studies present evidence for time- and dose-dependent decreases in the risk of developing ovarian cancers with the consumption of several NSAIDs (3–5), other studies failed to find any significant correlation or found that the reduction in risk was associated only with the use of particular NSAIDs (6, 7). Whether treatment with COX-2-selective inhibitors is beneficial for the prevention and/or treatment of ovarian cancer remains unknown.

The expression profiles of COX isoatypes in ovarian cancer remain puzzling, as most of the published reports mainly focused on COX-2 expression rather than COX-1 using the rationale that COX-2 is overexpressed in most tumors, whereas COX-1 is expressed primarily in normal tissues (Table 1). Furthermore, these studies mainly employed a single approach of immunologic detection of COX expression. It is possible that some of these studies used COX-2 antibodies that are nonspecific. Using multiple approaches, we recently showed that human epithelial ovarian cancer (EOC) manifests heightened expression of COX-1 but not COX-2 (8).

More than 85% of human ovarian cancers are EOCs, which originates from ovarian surface epithelial (OSE) cells (9). EOC is lethal, and effective treatment options for patients who present with the advanced disease are very limited. The high mortality rate is due to the lack of effective screening strategies identifying patients at high risk or those with early neoplastic lesions still amenable to treatment (10–12). The hallmark of EOC is the rapid growth and spread of solid i.p. tumors, often leading to ascitic fluid formation. It is the major cause of death among patients with gynecologic malignancies and is the fifth most common cause of death from cancer in the United States (13). EOCs are morphologically and biologically heterogeneous, making it difficult to define the molecular events underlying the disease development and progression. Morphologic criteria classify EOCs into four major...
types: serous, mucinous, endometriod, and clear cell (14). Although the causes of EOCs remain elusive, reproductive, endocrine, and hereditary factors play contributing roles in their genesis (9). Evaluation of human ovarian cancer specimens reveals several genetic alterations, including mutations in tumor suppressor genes, including \( p53 \), \( BRCA1 \), or \( BRCA2 \), and/or activating mutations or amplification of proto-oncogenes such as \( c-myc \), \( K-ras \), and \( Akt \). Thus, mutation or loss of tumor suppressor genes, amplification of growth stimulatory and/or suppression of death signaling pathways make certain individuals more susceptible to various cancers, including breast and ovarian cancers in women (12). However, the molecular mechanism by which these genes contribute to the initiation and/or progression of EOC remains poorly defined. Thus, the underlying causes and early events required for the progression of EOCs are among the least understood of all major human cancers.

Understanding the initiation and progression of EOC has been slow primarily because of the lack of suitable experimental models. Recently, an experimental model in which defined multiple genetic alterations can be introduced into mouse OSE cells in culture and in mouse ovaries has been developed (15). This system is based on avian RCAS virus delivery to the cells that are programmed to express the avian TVA receptor (16). Thus, genetically defined aberrations that are known to be involved in the genesis and growth of epithelial ovarian carcinomas can be introduced into the mouse ovarian epithelial cells \textit{ex vivo}. For example, the minimal genetic requirements for induction of a tumorigenic state in primary mouse ovarian epithelial cells were determined by introducing combinations of \( c-myc \), \( K-ras \), and \( Akt \) oncogenes into ovarian cells from \( p53 \) null mice. It was shown that a loss of the \( p53 \) gene, and the addition of any two of the \( c-myc \), \( K-ras \), and \( Akt \) oncogenes are sufficient to induce transformation of mouse primary OSE cells. Orthotopic implantation of infected OSE cells results in metastatic ovarian tumors that resemble human ovarian serous papillary carcinomas. Mouse OSE cell lines with defined genetic alterations have been generated from the \textit{ex vivo}–infected cells and the \textit{i.p.} tumors. More recently, three other groups have generated genetically

<table>
<thead>
<tr>
<th>COX-1</th>
<th>COX-2</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 NE</td>
<td>+(RT)</td>
<td>Cell line (38)</td>
</tr>
<tr>
<td>2 NE</td>
<td>+(RT, WB)</td>
<td>Cell line (39)</td>
</tr>
<tr>
<td>3 NE</td>
<td>+(WB)</td>
<td>Tumor (40)</td>
</tr>
<tr>
<td>4 NE</td>
<td>+(WB)</td>
<td>Tumor (41)</td>
</tr>
<tr>
<td>5 NE</td>
<td>+(WB)</td>
<td>Tumor (42)</td>
</tr>
<tr>
<td>6 NE</td>
<td>+(WB)</td>
<td>Tumor (43)</td>
</tr>
<tr>
<td>7 NE</td>
<td>+(WB)</td>
<td>Tumor (44)</td>
</tr>
<tr>
<td>8 NE</td>
<td>+(WB)</td>
<td>Tumor (45)</td>
</tr>
<tr>
<td>9 NE</td>
<td>+(WB)</td>
<td>Tumor (46)</td>
</tr>
<tr>
<td>10 NE</td>
<td>+(WB)</td>
<td>Cell line (26)</td>
</tr>
<tr>
<td>11 NE</td>
<td>+(WB)</td>
<td>Cell line (47)</td>
</tr>
<tr>
<td>12 NE</td>
<td>+(WB)</td>
<td>Tumor (48)</td>
</tr>
<tr>
<td>13 NE</td>
<td>+(WB)</td>
<td>Cell line (49)</td>
</tr>
<tr>
<td>14 NE</td>
<td>+(WB)</td>
<td>Tumor (50)</td>
</tr>
<tr>
<td>15 NE</td>
<td>+(WB)</td>
<td>Cell line (8)</td>
</tr>
<tr>
<td>16 NE</td>
<td>+(WB)</td>
<td>Tumor (51)</td>
</tr>
<tr>
<td>17 NE</td>
<td>+(WB)</td>
<td>Tumor (52)</td>
</tr>
<tr>
<td>18 NE</td>
<td>+(RT)</td>
<td>Cell line (53)</td>
</tr>
<tr>
<td>19 NE</td>
<td>+(RT)</td>
<td>Tumor (54)</td>
</tr>
<tr>
<td>20 NE</td>
<td>+(RT)</td>
<td>Tumor (55)</td>
</tr>
<tr>
<td>21 NE</td>
<td>+(RT)</td>
<td>Cell line (56)</td>
</tr>
<tr>
<td>22 NE</td>
<td>+(RT)</td>
<td>Tumor (57)</td>
</tr>
<tr>
<td>23 NE</td>
<td>+(RT)</td>
<td>Tumor (58)</td>
</tr>
<tr>
<td>24 NE</td>
<td>+(RT)</td>
<td>Tumor (59)</td>
</tr>
<tr>
<td>25 NE</td>
<td>+(RT)</td>
<td>Tumor (60)</td>
</tr>
<tr>
<td>26 NE</td>
<td>+(RT)</td>
<td>Tumor (61)</td>
</tr>
<tr>
<td>27 NE</td>
<td>+(RT)</td>
<td>Tumor (62)</td>
</tr>
<tr>
<td>28 NE</td>
<td>+(RT)</td>
<td>Tumor (63)</td>
</tr>
</tbody>
</table>

Abbreviations: NE, not examined; +, positive; RT, RT-PCR; −, negative; WB, Western blotting; +/-, mixed; IHC, immunohistochemistry; NB, Northern blotting; ISH, \textit{in situ} hybridization.
engineered mouse models of ovarian epithelial cancers (17–19). One study revealed that female transgenic mice expressing the transforming region of SV40 under control of the Mullerian inhibitory substance type II receptor gene promoter develop bilateral ovarian tumors (17), whereas the other two studies, using Cre-lox-mediated gene alterations in the ovarian surface epithelium, show that concurrent inactivation of p53 and Rb1 (18) or simultaneous activation of K-ras and inactivation of Pten (19) leads to the development of ovarian epithelial cancers in mice.

In this study, we used the mouse OSE cell lines and tumors described by Orsulic et al. (15) to examine the expression of COX isoforms and the effects of selective COX inhibitors on OSE tumor growth. We found that mouse OSE tumors express mainly COX-1 but not COX-2. More importantly, a COX-1-selective inhibitor SC-560 dramatically reduces tumor growth in vivo. The most abundant prostaglandin produced by OSE cells is prostacyclin (PGI2), the production of which is dose-dependently inhibited by SC-560. A COX-2-selective inhibitor celecoxib was ineffective in either reducing prostaglandin biosynthesis or tumor growth. These results suggest that COX-1 is an important player in this model of ovarian cancer and that selective COX-1 inhibitors may have potential for use in the treatment and prevention of EOC in humans.

Materials and Methods

Cell lines and culture. To generate C1 (genotype: p53−/−, myc, K-ras) and C2 (genotype: p53−/−, myc, Akt) cell lines, ovarian explants from K5-TVA/p53−/− mice were infected with different combinations of RCAS viruses carrying human c-myc, mouse K-rasG12D, and mouse myr-Akt1 oncogenes. The cell cultures were passaged in the presence of viruses for 3 weeks, after which they consisted of a pure population of transformed OSE cells. T1 and T2 cell lines were derived by isolating cells from tumors that were generated by orthotopic placement of C1 and C2 cells into nude mice, respectively. The C1, C2, T1, and T2 cell lines readily developed tumors when transplanted into immunocompromised mice. These OSE cells were propagated in DMEM containing 10% fetal bovine serum (FBS), 100 units/ml of penicillin, and 100 μg/ml streptomycin.

Allografting of ovarian surface epithelial cells and tumor growth. T2 OSE cells were used for tumor growth studies in vivo. A suspension of 2.5 × 10^6 T2 cells was placed under the dorsal skin of female athymic nude mice (nu/nu, 5-6 weeks old). Tumor growth was measured every 2 to 4 days by direct measurement of tumor dimensions. COX-1-selective inhibitor (SC-560) or COX-2-selective inhibitor (celecoxib), the cells were incubated for 4 hours. To determine the effects of COX inhibitors on the basal levels of prostaglandins, cells were cultured for 4 and 16 hours without arachidonic acid. The medium was analyzed for prostaglandin levels by gas chromatography/negative ion chemical ionization mass spectrometric assay (21). PGI2 was measured as its stable metabolite 6-keto-PGF1α. Arachidonic acid was dissolved in ethanol, whereas the COX inhibitors were dissolved in DMSO. Cells cultured in vehicle contained 0.1% ethanol and 0.1% DMSO.

Cell growth assay. Cell viability was measured by trypan blue exclusion assay. Briefly, T2 cells (0.5 × 10^5 per well) were plated in 6-well plates. After culture overnight, the cells were washed twice with PBS, and treatment was initiated with serum-free medium containing either 10% FBS, 0.1% DMSO, SC-560, or celecoxib for the indicated times. Viable cells were counted by trypan blue exclusion assay.

Apoptosis assays. The protocol used to assess apoptosis has previously been published by us (23). T2 cells (1.5 × 10^5 per well) were plated in 6-well plates. After culture overnight, the cells were washed twice with PBS and incubated in serum-free medium containing either 10% FBS, 0.1% DMSO, SC-560, or celecoxib for 3 days. The assay for apoptotic cells was done using a TACS Annexin V-FITC Apoptosis Detection Kit according to the manufacturer's instructions (R&D Systems, Inc., Minneapolis, MN). For this assay, the cells were harvested, washed, and incubated with Annexin V-FITC and propidium iodide. After washing, the cells were analyzed by flow cytometry. The combination of Annexin V-FITC and propidium iodide allowed us to differentiate between early apoptotic cells (Annexin V-FITC positive), late apoptotic cells (Annexin V-FITC and propidium iodide positive), necrotic cells (propidium iodide positive), and viable cells (both negative).

Immunostaining of proliferating cell nuclear antigen and Ki67. Formalin-fixed paraffin-embedded tumor sections (10 μm) were subjected to immunostaining using a proliferating cell nuclear antigen (PCNA) or Ki67 antigen staining kit according to the manufacturer's instructions (Zymed Laboratories, Inc., San Francisco, CA and Novocastra Laboratories Ltd., Newcastle, United Kingdom). Brown color indicates the sites of positive staining for both PCNA and Ki67 nuclei.

Terminal deoxynucleotidyl transferase–mediated nick-end labeling staining. Formalin-fixed paraffin-embedded tumor sections (10 μm) were subjected to terminal deoxynucleotidyl transferase–mediated nick-end
Results

COX-1 levels are increased in oncogenic mouse ovarian surface epithelial cells and tumors. Our first objective was to determine whether mouse OSE cells lacking functional p53 with activation of oncogenic pathways express COX-1 and/or COX-2. Several mouse ovarian cancer cell lines that contain combinations of defined genetic alterations were generated. C1 (genotype: p53

mrc, K-ras) and C2 (genotype: p53

isoforms COX-1 and COX-2 expression in these cell lines. The results of Northern hybridization are comparable with those of human ovarian malignancies (8). Western blot analysis of COX-1 and COX-2 expression in C1, C2, T1, and T2 OSE cell lines show that COX-1 is the predominant pathway for generating prostaglandins in EOCs in mice, and these results support our previous observations in human EOCs (8).

Prostaglycerin is the major prostaglandin produced in ovarian surface epithelial cells and its level is attenuated by inhibition of COX-1 activity. Prostaglycerin E2 (PGF2β) is the major prostaglandin produced by OVCAR-3 cells, a human EOC cell line, although PGF2α production was also substantial (8). Thus, we sought to characterize the prostaglandin profile in mouse OSE cells expressing COX-1. The levels of prostaglandins were measured by gas chromatography/mass spectrometry in serum-free medium in which cells were cultured in the presence or absence of arachidonic acid. PG2 is the major prostaglandin produced and its levels in T2 cells increase in an arachidonic acid concentration-dependent manner (Fig. 3A and B). PGF2β is also detected in the medium but at levels much lower than PG2. Levels of PGF2α and TXB2 were very low or below detection levels. A COX-1-selective inhibitor SC-560 dramatically reduced the PGF2α levels in a dose-dependent manner, whereas celecoxib, a COX-2-selective inhibitor, had little effect (Fig. 3C); levels of PGF2α were not altered by either SC-560 or celecoxib. We observed similar prostaglandin profiles in C1 and C2 OSE cell lines (data not shown), T1 cells have low levels of PGF2α (data not shown), which is not surprising because these cells express low levels of COX-1, and an undetectable level of COX-2 (Fig. 4A). To determine whether the basal levels of PGF2α without arachidonic acid are altered by the COX-1 inhibitor with time, T2 cells were cultured for 4 or 16 hours in the presence or absence of SC-560. We observed that the basal levels at 4 hours were higher than those at 16 hours (3,900 ± 200 versus 1,200 ± 200 pg/mL, n = 3). However, SC-560 at 2, 5, or 10 μmol/L was equipotent at 4 hours in further lowering the levels of PGF2α (3,900 ± 200 versus ~200 ± 20 pg/mL, n = 3 for each concentration), whereas at 16 hours, SC-560 at 2 μmol/L was less potent than 5 or 10 μmol/L in reducing such levels (400 ± 70 versus ~200 ± 20 pg/mL, n = 3 for each concentration). These results suggest that a relatively higher concentration of SC-560 is necessary to sustain a reduced basal level of PGF2α for an extended period. We next examined the expression of prostacyclin synthase (PGIS), the enzyme that catalyzes conversion of PGH2 to prostacyclin, in OSE cell lines.
and allografted tumors. The results of Western blot analysis showed that these cell lines express PGIS protein (Fig. 4A). The expression of PGIS was also evident in tumor tissues as determined by Western blotting and in situ hybridization. The presence of PGIS protein was clearly evident in tumor samples, but the levels were lower in tumors derived from C2 and T1 cell lines (Fig. 4B). The results of in situ hybridization provide evidence that PGIS is expressed in these tumors. The expression was primarily restricted to the growing epithelial cells but not in the host stroma (Fig. 4C). Collectively, these results provide evidence that PGI2 is the major prostaglandin produced by OSE cells and tumors, and this production is sensitive to inhibition by SC-560, but not celecoxib.

SC-560, a COX-1-selective inhibitor, suppresses ovarian surface epithelial tumor growth in vivo. Our observation of predominant expression of COX-1 in oncogenic OSE cell lines and tumors derived from these cells suggested that COX-1 inhibition would inhibit or retard tumor growth of allografted OSE cells in vivo. To address this issue, we initiated further studies with T2 cells, which primarily express COX-1. These cells were allografted under the dorsal skin of female nude mice. After tumor engraftment (7 days), these mice were gavaged with vehicle, SC-560 (3 mg/kg body weight) or celecoxib (50 mg/kg body weight) twice a day for 18 days or 50 days. These doses were chosen for their specificity in inhibiting COX isotypes (25). Tumor volume was measured every 2 to 4 days for 59 and 64 days for the short-term and long-term treatment groups, respectively. As shown in Fig. 5, whereas the tumor growth increased throughout the period examined in the vehicle-treated or celecoxib-treated group, the growth was substantially suppressed in the SC-560-treated group even when the drug treatment was withdrawn after 18 days. Tumor growth was also suppressed in allografted mice treated with SC-560 for a longer period, but the reduction in tumor growth was less dramatic than the short-term treated

---

Figure 2. Tumors generated from OSE cancer cell lines show similar expression of COX-1 and COX-2 as observed for cell lines. A, Western blot analysis of COX-1 and COX-2 expression in tumors. B, Northern hybridization of Cox-1 and Cox-2 in tumor samples. rPL7 is a housekeeping gene. C, in situ hybridization of Cox-1 and Cox-2 in tumor sections. Bar, 500 μm. D, in situ hybridization of Cox-1 and Cox-2 in normal ovaries. Wild-type mice were treated with 5 IU of pregnant mare serum gonadotropin for 48 hours followed by 5 IU of human chorionic gonadotropin to stimulate follicular growth for preparation of ovulation at a defined time point. Ovarian sections from representative mice at 8 hours after hCG treatment. Arrowheads, surface epithelium. Bar, 200 μm.
group. Nonetheless, these results suggest that COX-1 is a potential target for the prevention and treatment of ovarian cancer.

**Discussion**

This investigation reveals that COX-1 is the dominant pathway responsible for generating prostaglandins in EOCs in mice. These results support our recent findings of COX-1 overexpression in human EOCs (8). Because oncogenes, cytokines, and growth factors are known to up-regulate COX-2, it is often assumed that COX-2 derived prostanoids function as downstream signaling molecules in tumorigenesis. Whereas this is true for colorectal cancer and many other extracolonic cancers including breast, prostate, uterus, lung, head, and neck cancers (2, 27–29), the story of COX expression in ovarian cancer has become highly controversial and requires careful reevaluation. To our knowledge, there are 28 published reports (Table 1) that investigated COX expression in ovarian cancers. Interestingly, 20 of 28 reports did not examine COX-1 levels; attempts were made to examine only COX-2 expression and among these studies, not all of the samples examined were positive for COX-2 expression. In addition, 9 of 28 reported studies only used human ovarian cancer cell lines but not tumor samples. More importantly, except our study in which multiple approaches were used to confirm COX-1 expression (8), all other studies on human tumor samples used a singular approach of immunodetection of COX expression (Table 1). The results of immunodetection of COX-1 and COX-2 may lack specificity due to known cross-reactivity of many available antibodies and may lead to erroneous interpretation. Furthermore, it is not clearly stated in many of the reports whether samples were excluded from patients that had undergone cytoreductive therapy, a treatment commonly employed for advanced ovarian cancers.
malignancy. It is well established that drugs used in cytoreductive therapy would likely induce COX-2 (30), and it is unclear whether elevated COX-2 levels observed in these studies is primarily due to the oncogenic transformation of ovarian epithelial cells or secondary to the use of cytotoxic agents for the treatment of the primary disease. Our previous report on human EOCs (8), and our present finding of COX-1 expression in mouse OSE tumors lead us to seriously consider that COX-1 is the dominant pathway for generating prostaglandins in ovarian cancers.

It is interesting to note that COX-1 is expressed at much higher levels than COX-2 in OSE cells and tumors overexpressing c-myc and K-ras (C1 and T1) or c-myc and Akt (C2 and T2). This is surprising because K-ras is known to regulate COX-2 expression in several other systems (31, 32). This raises a question as to the underlying mechanism for regulation of COX-1 in OSE tumors. As shown previously (22) and reported here (Fig. 2D), COX-1 and COX-2 are expressed in granulosa cells of mouse ovarian follicles before ovulation in a temporal manner, but neither COX isoform is detectable in the ovarian surface epithelium. This suggests that oncogenic transformation leads to the expression of COX-1 in the ovarian surface epithelium. One might also argue that mRNA stability accounts for increased COX-1 and depressed COX-2 expression in ovarian tumors. Our preliminary experiments of Northern hybridization with OSE cells in the presence of Actinomycin D argue against this possibility (data not shown).

Thus, the mechanism by which COX-1 expression is regulated in both OSE cells and tumors is under active investigation in the laboratory.

A lack of suitable animal models for ovarian cancer has been a major drawback in obtaining useful mechanistic information on ovarian tumorigenesis. Although there are several human ovarian carcinoma cell lines that generate tumors upon xenografting into immunocompromised mice, the ovarian origin of these cell lines is not well characterized. Most human ovarian tumors are believed to arise from the single layer of epithelial cells that covers the ovarian surface (9). However, a recent report describes a genetically defined model of human EOC and should be useful for studying this disease (33). In this respect, mouse OSE cell lines with defined genetic
alterations provide alternative approaches for studying EOCs that could be relevant to humans. It would be interesting to see whether COX-1 expression is common to other models of EOCs in mice produced by alteration of different genes (17–19).

Unrestricted cell proliferation and reduced apoptosis are hallmarks of transformed cells. A plethora of signaling pathways and molecules influences these processes. Our results of reduced tumor growth with decreased cell proliferation and accelerated apoptosis following SC-560 treatment, not with celecoxib, suggest that COX-1 derived prostaglandins promote OSE tumor growth at least by influencing cell proliferation and apoptosis. Because PGI2 is the major prostaglandin produced by mouse OSE cells and tumors, we suspect that this prostaglandin is involved in these processes. The next question concerns the downstream signaling pathways affected by PGI2. PGI2 normally binds to and activates its cognate G-protein-coupled cell surface receptor IP. The activation of IP results in increased levels of intracellular cyclic AMP, the second messenger system linked to PKA signaling (34). There is also evidence that PGI2 functions as an endogenous ligand for the nuclear receptor PPARγ (21). We have previously provided evidence for the participation of both PGI2 and PGE2 in the activation of PPARγ involved in colorectal and intestinal cancers (23, 35). Although both IP and PPARγ are expressed in mouse OSE cells and tumors (data not shown), whether each of these pathways singularly or cooperatively participates in tumor growth is the subject for future research. Recently, a COX-1 splice variant coined as COX-3 has been identified and acetaminophen, an analgesic/antipyretic agent, inhibits its activity (36). Whether this isoform is involved in ovarian cancer is not known.

The effects of SC-560 in attenuating tumor growth in vivo are remarkable even after withdrawal of the drug treatment. Our preliminary results also show that C2 OSE cells allografted under the dorsal skin of immunocompromised γc/Rag2 double mutant mice, lacking natural killer cells and T and B lymphocytes, also produce tumors, and the tumor growth is attenuated after short-term (14 days) treatment with SC-560 but not celecoxib (data not shown). We speculated that long-term treatment with SC-560 would be even more dramatic but were surprised to see that continuous treatment was less effective than short-term therapy. This may reflect a tumor’s ability to develop drug resistance, a well-known trait of ovarian cancers (37). Because long-term use of certain COX-2 inhibitors are linked to hypertension, peripheral

Figure 6. COX-1 selective inhibitor SC-560 attenuates OSE tumor cell proliferation and accelerates apoptosis. A, cell growth assay. T2 Cells (0.5 × 105) were seeded in 12-well plates and incubated with DMSO (vehicle, 0.1%), SC-560 or celecoxib at different concentrations for indicated days. Cell numbers were counted from triplicate wells. Points, mean of three independent experiments; bars, ±SE. B and C, apoptosis assay. Cells were treated with DMSO, SC-560, or celecoxib at indicated concentrations for 3 days after removal of the serum from the culture media. Number of apoptotic cells was determined by flow cytometry using an Annexin V-FITC kit. Columns, mean of percent apoptotic cells in three separate experiments; bars, ±SE. D, immunostaining of PCNA, Ki67, and TUNEL in tumors. Tumor samples used in this study were derived from nude mice in Fig. 5 legend. Bar, 50 μm.
edema, and an increased risk of serious heart problems in some patients, aspirin as a preferred COX-1 inhibitor may have more meaningful application in combating ovarian tumors. In conclusion, our previous study on mouse EOCs and the present investigation on mouse EOCs using multiple approaches provide convincing evidence that COX-1 not COX-2 is the major prostanoid generating pathway operative in ovarian cancers of epithelial origin. These results present COX-1 as a potential target for the prevention and treatment of human EOCs.

Acknowledgments

Received 10/22/2004; revised 2/13/2005; accepted 2/16/2005.

Grant support: USPS grants, P01-CA77839, R37 HD12304, R37 DK7297, and GM42056; Mary Kay Ash Charitable Foundation; American Cancer Society Institutional (T. Daikoku) and National Cancer Institute grant CA103924-01 (S. Orsulic).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Mark Geraci for providing us with the PGIS cDNA and Jennifer Jones for her help in PGIS Western blotting.

References


Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer

Takiko Daikoku, Dingzhi Wang, Susanne Tranguch, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/9/3735

Cited articles
This article cites 63 articles, 24 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/9/3735.full#ref-list-1

Citing articles
This article has been cited by 13 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/9/3735.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://cancerres.aacrjournals.org/content/65/9/3735.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.